Placebo‐controlled, randomized, evaluator‐blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women
Authors:
Open Access
- 27 December 2000
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (12) , 1663-1670
Abstract
Background: Bisphosphonates are effective treatments for osteoporosis. Since some primary amino bisphosphonates are associated with oesophageal injury, we conducted a study of the upper gastrointestinal effects of risedronate, a pyridinyl bisphosphonate.Methods: Healthy, postmenopausal women received risedronate 5 mg (n=26), aspirin 2600 mg (n=27), or placebo (n=27) daily for 14 days and underwent endoscopy at baseline, Day 8 and Day 15.Results: Oesophageal erosions were noted in one subject in the aspirin group, two in the placebo group, and none in the risedronate group, and an ulcer in one aspirin‐treated subject. Gastric erosions and ulcers were observed most frequently in the aspirin group. Gastric ulcers were noted in eight subjects in the aspirin group, one in the placebo group, and none in the risedronate group (P=0.010, placebo vs. aspirin; P=0.002, risedronate vs. aspirin). Duodenal erosions and ulcers were observed in the aspirin group only. Gastroduodenal erosion scores of three or more occurred more frequently in the aspirin than in the risedronate and placebo groups (P < 0.001).Conclusions: Risedronate 5 mg was not associated with oesophageal or gastroduodenal ulcers in healthy, postmenopausal women, a population representative of patients who will receive risedronate in the clinical setting.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized TrialJournal of Bone and Mineral Research, 2000
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology, 1999
- Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulationsInternational Journal of Pharmaceutics, 1999
- Alendronate gastric ulcersAlimentary Pharmacology & Therapeutics, 1999
- How does citric acid increase urease activity in vivo?Gastroenterology, 1998
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseasesCurrent Therapeutic Research, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosisThe Journal of Clinical Endocrinology & Metabolism, 1994
- Rolling review: upper gastrointestinal bleedingAlimentary Pharmacology & Therapeutics, 1993